Confo Therapeutics NV, which has a new approach to drug discovery, has raised €30 million in a Series A financing round – one of the largest A financing rounds in Belgium. The round was led by the Dutch early-stage investor BioGeneration Ventures and co-led by Wellington Partners with participation by eight other institutions including Vlaams Instituut voor Biotechnologie (VIB), a co-founder of the company.
